On June 22, 2023 Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that the first patients have been dosed in each arm of its ongoing REVERT LIVER CANCER trial (Press release, Tvardi Therapeutics, JUN 22, 2023, View Source [SID1234632854]). The trial is evaluating safety and clinical activity of TTI-101 as monotherapy and in combination with standard of care therapy in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC)
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The REVERT LIVER CANCER trial is currently enrolling HCC patients at top US cancer research institutes and is designed to evaluate TTI-101 across multiple lines of therapy:
• TTI-101 alone for patients previously treated with up to three prior lines of systemic therapy
• TTI-101 in combination with pembrolizumab (Keytruda) for patients previously treated with immunotherapy
• TTI-101 in combination with atezolizumab (Tecentriq) and bevacizumab (Avastin) for treatment naïve patients
Liver cancer is the sixth most commonly diagnosed cancer and the third most common cause of cancer death. HCC is the most common form of liver cancer; however, treatment options for the disease are limited and overall prognosis for survival is poor, with a 5-year survival rate of 18%. TTI-101’s target, STAT3, is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment. TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3.
"Enthusiasm for our HCC study continues to expand with recently presented clinical data demonstrating TTI-101 monotherapy has robust efficacy in heavily pretreated patients with HCC, published preclinical work highlighting TTI-101’s synergy with immunotherapy, and the FDA’s Fast-Track Designation for TTI-101 in HCC," said Imran Alibhai, PhD, CEO of Tvardi Therapeutics. "This is the second of three Phase 2 trials Tvardi has initiated to address diseases driven by STAT3."
For more information about the REVERT LIVER CANCER trial currently enrolling at sites throughout the US, please visit ClinicalTrials.gov (NCT05440708).